They took these cells from HAART-treated patients who have shown no detectable traces of the virus for at least six months.
When the researchers forced the cells to differentiate into white blood cells in the lab, they found that the HIV genome in these cells in about 40 percent of the donors.
They also took cells from the bone marrow of healthy people and showed that the virus killed some cells, but in other cells the virus integrated into the cells' chromosomes and did not reproduce.
The cells grew as if they were uninfected by the virus.
"If the drugs are on-board, the virus is still being made but it is not doing much harm because it can't spread," says Collins.
In the absence of the drugs, the infection renews, and patients need to return to the therapy and stay on it.
"If you shorten the therapy even to two years, that would dramatically change things," she said, by bringing down costs and allowing the therapy to be used more widely in poor countries.
The study has been published in Nature Medicine.
Source-ANI
RAS